Date Hour Room Track
28th November,2017 12 am Track 3
  • What are the consequences of the increasing interactions and partnerships between pharma and VCs at the initial stages of pre-seed, seed and Series A?
  • Are we talking Entente Cordiale or open rivalry?
  • What is the part to play for Corporate VC in that context?

Continue your tour